Malaysia-EU FTA Draws Political Criticism For Impact On Drug Access
This article was originally published in PharmAsia News
Executive Summary
Concerns have been raised by members of parliament in Malaysia that a proposed Free Trade Agreement with the European Union may limit drug access in the Malaysian market. Malaysia and the EU are currently negotiating an FTA and are expected to meet in June for a second round of meetings, and the agenda includes discussion of a clause to extend the patent life for innovative medicines